Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials

被引：0

作者：

Silverberg, Jonathan ^{[1
]}

Thaci, Diamant ^{[2
]}

Seneschal, Julien ^{[3
,4
]}

Gold, Linda Stein ^{[5
]}

Blauvelt, Andrew ^{[6
]}

Simpson, Eric ^{[7
]}

Chu, Chia-Yu ^{[8
,9
]}

Liu, Zhuqing ^{[10
]}

Lima, Renata Gontijo ^{[10
]}

Pillai, Sreekumar ^{[10
]}

Guttman-Yassky, Emma ^{[11
]}

机构：

[1] George Washington Univ, Sch Med, Washington, DC USA

[2] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[3] Univ Bordeaux, Bordeaux, France

[4] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Bordeaux, France

[5] Henry Ford Hlth Syst, Detroit, MI USA

[6] Oregon Med Res Ctr, Portland, OR USA

[7] Oregon Hlth & Sci Univ, Portland, OR USA

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[10] Eli Lilly & Co, Indianapolis, IN USA

[11] Icahn Sch Med Mt Sinai, New York, NY USA

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P075

引用

页码：62 / 62

页数：1

共 50 条

[41] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
Dermatology and Therapy, 2023, 13 : 595 - 608
[42] Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials
Hanania, Nicola A.
Noonan, Michael J.
Corren, Jonathan
Korenblat, Phillip
Zheng, Yanan
Putnam, Wendy
Murray, Elaine
Abelardo, Connie
Scheerens, Heleen
Maciuca, Romeo
Gray, Sarah
Doyle, Ramona
McClintock, Dana
Matthews, John G.
Yen, Karl
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB402 - AB402
[43] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Wang, Shangshang
Zhang, Litao
Liang, Yunsheng
Zhang, Shifa
Wang, Jingyan
Man, Xiaoyong
Ji, Chao
Chen, Rixin
Xiang, Guang
Meng, Zudong
Yang, Chunjun
Cheng, Hao
Wang, Qi
Li, Lin-feng
Zhang, Siping
Ding, Yanfeng
Zhu, Quangang
Qin, Lanying
Li, Yumei
Lu, Qianjin
Xia, Li
Cao, Shuanglin
Yu, Chunshui
Duan, Xinsuo
Wu, Liming
Zhang, Chunlei
Jiang, Congjun
Wang, Wei
Xu, Jinhua
DERMATOLOGIC THERAPY, 2025, 2025 (01)
[44] Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2)
Simpson, E. L.
Bieber, T.
Guttman-Yassky, E.
Beck, L. A.
Blauvelt, A.
Cork, M. J.
Silverberg, J. I.
Deleuran, M.
Kataoka, Y.
Lacour, J. -P.
Kingo, K.
Worm, M.
Poulin, Y.
Wollenberg, A.
Soo, Y.
Graham, N. M. H.
Pirozzi, G.
Akinlade, B.
Staudinger, H.
Mastey, V.
Eckert, L.
Gadkari, A.
Ardeleanu, M.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 79 - 79
[45] EFFICACY AND SAFETY OF CM310 IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN CHINA
Zhang, Jianzhong
Yang, Bin
Li, Jingyi
Ding, Yangfeng
Wu, Liming
Zhang, Litao
Wang, Jinyan
Zhu, Xiaohong
Zhang, Furen
Tao, Xiaohua
Li, Yumei
Zhang, Chunlei
Li, Linfeng
Lu, Jianyun
Diao, Qingchun
Lu, Qianjin
Man, Xiaoyong
Li, Fuqiu
Xia, Xiujuan
Cheng, Hao
Zhao, Yan
Chen, Bo
Yan, Jinchun
Zhao, Guoqing
Jia, Yingmin
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 20 - 20
[46] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
Ebisawa, Motohiro
Kataoka, Yoko
Tanaka, Akio
Nagao, Mizuho
Laws, Elizabeth
Mortensen, Eric
Nawata, Hisakatsu
Arima, Kazuhiko
Watanabe, Daisuke
Lu, Xin
Maloney, Jennifer
Dubost-Brama, Ariane
Bansal, Ashish
Yahata, Kenji
ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
[47] Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Simpson, Eric L.
Flohr, Carsten
Eichenfield, Lawrence F.
Bieber, Thomas
Sofen, Howard
Taieb, Alain
Owen, Ryan
Putnam, Wendy
Castro, Marcela
DeBusk, Kendra
Lin, Chin-Yu
Voulgari, Athina
Yen, Karl
Omachi, Theodore A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 863 - +
[48] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Simpson, Eric L.
Merola, Joseph F.
Silverberg, Jonathan, I
Reich, Kristian
Warren, Richard B.
Staumont-Salle, Delphine
Girolomoni, Giampiero
Papp, Kim
de Bruin-Weller, Marjolein
Thyssen, Jacob P.
Zachariae, Rebecca
Olsen, Christiana K.
Wollenberg, Andreas
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
[49] Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials
Simpson, E. L.
Rahawi, K.
Hu, X.
Chu, A. D.
Nduaka, C.
Jazayeri, S.
Lio, P.
Lynde, C.
Schuttelaar, M. L. A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, : 1863 - 1870
[50] A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
Zhang, Chunlei
Yan, Kexiang
Diao, Qingchun
Guo, Qing
Jin, Hongzhong
Yang, Sen
Chen, Xiang
Lei, Tiechi
Wu, Jianhua
Yu, Hong
Zheng, Min
Gao, Xinghua
Sinclair, Rodney
Zhu, Yi
Xu, Qian
Xu, Jinhua
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (01) : 95 - 102

← 1 2 3 4 5 →